• Day One Biopharmaceuticals (NASDAQ: DAWN) announced topline results from the ongoing Phase 2 FIREFLY-1 trial evaluating tovorafenib (DAY101) as a monotherapy in recurrent or progressive pediatric low-grade glioma (pLGG). 
• Pediatric low-grade glioma is the most common brain tumor diagnosed in children.
• Additional data will be submitted for presentation at an upcoming medical meeting in the second quarter of 2023.
• Overall response rate (ORR) of 64% and clinical benefit rate (CBR) of 91% were observed in 69 heavily-pretreated, RANO-evaluable patients.
• Related: This Pediatric Cancer Company Makes It To Analyst's Conviction List.
• Based on 77 treated patients, safety data indicated monotherapy tovorafenib to be generally well-tolerated. 
• The most common side effects reported related to tovorafenib were change in hair color (75%), increased creatine phosphokinase (64%), anemia (46%), fatigue (42%), and maculopapular rash (42%).
• In addition to FIREFLY-1, Day One is expanding the development of tovorafenib as a front-line therapy for patients newly diagnosed with pLGG. 
• The global, Phase 3, registrational FIREFLY-2/LOGGIC clinical trial is evaluating once-weekly monotherapy tovorafenib in newly-diagnosed patients with pLGG harboring a known activating RAF alteration.
• Price Action: DAWN shares are up 23.70% at $26.39 during the premarket session on the last check Monday.

See more from Benzinga

• Tesla's Delivery Wait Times Go Up, China Wants To Secure License For Generic Version Of Pfizer's Paxlovid, India-Made iPhone Exports Surpass $2.5B: Today's Top Stories
• Ocugen Announces Encouraging Data From Late-Stage COVID-19 Vaccine Study
• Obama Says Republicans Are 'Obsessed' With 2 Things — One Of Them Is Trump

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.